Member Info for Basser1

Dilley has been very cagey about saying anything about SRA 737. But he did state in one announcement that SRA 737 could turn out to be more lucrative than Momelotinib in the longer term. He is keeping it and they will go into partnership - hopefully with Merck as Thoth has said.

There is no way that a bidder is going to get a takeover cheaply. TYK 2 is too hot a property in the scientific world.And we have two patented TYK2 molecules for autoimmune and cancer. A first offer would quickly be followed by improved bids IMO.

Yes indeed a good end to the week. The share price has been remarkably robust considering the organised short. At least the penny has dropped that it would never go far below 7p. Different strategy today allowing a build in the share price and then sell into the afternoon. Can anyone who knows the intricacies of the market let me know how this short is ever going to make money? ( Especially if good news follows in the next fortnight.

Good article. But does influenza for example lead to as many different long term illnesses as Covid? The article does not seem to factor in any lasting effects in weighing up how we will be treating it ie through vaccinations?

Quote “ it seems unlikely that the virus itself is still at work. Most of the studies have shown that after a few weeks your pretty much clear of it, so I very much doubt it’s an infectious consequence.A possibility is that Long Covid is caused by the immune system going haywire and attacking the rest of the body. In other words Long Covid is an autoimmune disease. SARS cov2 is like a nuclear bomb in terms of the immune system as it blows everything up. Some of these changes might linger as has been seen in the aftermath of other viral infections”.
The current Government strategy relying on vaccinations is unlikely to stop further increases in long covid cases. Noticed the the Government’s new research programme into long covid has given a grant to Cardiff University to investigate the possibility of an immune response overreaction. Further proof that the development of therapeutic options are equally as important as vaccines and that the WHO has formally recommendation that TYK2 should be considered in in development of further trials.
Sareum really is in the right place at the right time and I can see why Thoth and others are putting forwarded eye watering financial estimates for SD1801. They are certainly not beyond the realms of possibility.

Elap - I am not against a takeover at some stage. But if any takeover offer is coming soon it will not be able to represent the true scientific potential of the assets ie SDC 1801, SDC1802 and SRA737. The first two have not even begun trials and We still don’t know when Sierra is likely to relaunch SRA737 in new combo trials. So the offer would be cautious probably with low up front payment and then the rest paid on results. I think the Sareum BoD will favour all the assets being in early trials before accepting any form of Takeover. Which points to around the end of the year or early next year. An offer now would not be worth the paper it is written on. It’s Hold for Gold as far as I am concerned.

It’s not volatile. Share price has gone from under1p to the current 7p in under a year. Nothing goes up in a straight line. Patience has been the key for long term holders and it has seen them well rewarded.If you do not like the ups and downs you may want to consider selling on the up?

Aber - you are far too polite. I call them Ch———-g Ba—————-s

14.24.05 Buy 7.3222
14.24.29 Buy 7.3222
13 secs later 14.24.52 Unknown. 7.433
What a joke. How do they get away with it! More scrutiny needed urgently.

I have just sent an Email to the FDA in the US with a complaint about the non publication of the SRA737 phase1/2 trials within the required 12 months period after completion. Will be interesting to see it’s response - if I get a response!

Compare the close price with the las half hours trading. And obviously wait for late published buys and buys hidden as sells.

This constant playing around with the share price is get wearing. Two late trades yesterday totalling 1,200,000 share are shown as sells with price 7.30. Close price was 7.20 ffs. Can’t continue like this.

Yes they have sold many millions of shares trying to get this below 7p. The message to them is that the bottom baseline is 7p and no lower. A time will come soon where they have to start buying them back as news is expected on a number of fronts. I Sense a wailing and gnashing of teeth episode.

P.nis

Latest news on long covid - symptom can include reduced ***** size. If true, now we would really have a treatment that would be in big demand.

The clock is ticking. We are now over half way though July. I would have thought that an announcement is now due if the Government’s timetable to get new treatments into hospitals by the end of the year is to be met.

To be honest, It would seem odd not to see an offer for Agile support from the Government given the wide support for TYK2 in major scientific papers ( Nature, Lancet) and the WHO. Whether an offer would be accepted by Sareum is another matter given that a number of alternatives seem to be available (as stated in the RNS).

BoilB. Interesting. Agile Clinical Trial no1 is still to be confirmed( last updated in May). Seem to recall that Sareum was listed at no1 in the list of 13 candidates that received the research grants back in December. Could be something in it, or just coincidence.

The problem for all Conservative PMs is that they are hounded and nearly always give in to the right wing dinosaurs within the Tory Party. It is their Achilles heel. What makes it worse is that as soon as the dinosaurs get their way they disappear back under the stones they emerged from and you won’t hear a peep from them until the next issue appears where their interests are involved - they never have to face up to the consequences of their actions.

Let’s hope the PMs war on Covid does not turn into a Churchillian Gallipoli.